RCUS

MKT CAP:$3B

Arcus Biosciences Inc

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Healthcare·Biotechnology·🇺🇸·NYSE

Stock Price

$23.32+$0.03 (+0.13%)

Jun 8, 2026

52W High $26.6252W Low $7.95

Company Details

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of...

CEO

—

IPO Date

Mar 15, 2018

Website

arcusbio.com

Key Metrics TTM

Revenue

$236M

+67.4% YoY

Net Income

-$369M

EPS (Diluted)

Free Cash Flow

-$489M

Revenue / Share

$1.88

Gross Margin

97.0%

Operating Margin

-168.6%

Net Margin

-156.4%

FCF Margin

-207.2%

P/S

13.7x

P/E

Earnings Reports

Q2 2026

Aug 5, 2026

PENDING

Q1 2026

May 5, 2026

$17M-39.3%

FY 2025

Feb 25, 2026

$247M-4.3%

Q4 2025

Feb 25, 2026

$33M+26.9%

Q3 2025

Oct 28, 2025

$26M-45.8%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee